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CLINICAL IMPLICATIONS OF
BASIC RESEARCH
 
G PROTEINS IN MEDICINE
 
T
 
HE
 
 award of the 1994 Nobel Prize in Physiology or
Medicine to Alfred G. Gilman and Martin Rodbell for
the discovery of G (guanine nucleotide–binding) pro-
teins and their role in cellular signal transduction has
focused attention on the manifold functions of these
ubiquitous molecules and on the ways in which they
can become disordered in human diseases. These mol-
ecules couple a dizzying array of receptors at the cell
surface (including those for neurotransmitters such as
epinephrine, hormones, odorants, and photons of light)
with a variety of intracellular effectors exposed at the
inner surface of the plasma membrane (including en-
zymes such as adenylate cyclase and ion channels).
This design explains how such extracellular “first mes-
sengers” as hormones generate intracellular “second
messengers” such as cyclic AMP (cAMP) — an idea
originally proposed by Earl Sutherland (a previous No-
bel laureate) more than 30 years ago.
As Figure 1 shows, G proteins function essentially as
on–off switches for cellular signaling. They consist of
three nonidentical protein subunits (
 
a
 
, 
 
b
 
, and 
 
g
 
) that
are noncovalently associated. In the resting state,
the nucleotide guanosine diphosphate (GDP) is tightly
bound to the 
 
a
 
 subunit. This is the “off” position of
the G-protein switch. When the membrane receptor is
activated — for example, by the binding of a hormone
— it interacts with the G protein, causing GDP to
dissociate from the 
 
a
 
 subunit. GDP is rapidly replaced
by guanosine triphosphate (GTP), which activates the
G protein. This in turn leads to its dissociation into
 
a
 
-subunit and 
 
bg
 
-subunit complexes, either or both of
which can activate effectors. The switch is now “on.”
Within a few seconds the 
 
a
 
 subunit, which is a guan-
osine triphosphatase (GTPase), hydrolyzes GTP to
GDP. This inactivates the 
 
a
 
 subunit, allows it to reas-
sociate with the 
 
bg
 
 subunit, and resets the switch to the
off position. Many different G proteins mediate diverse
physiologic effects by this mechanism. 
Given the ubiquitous distribution of G proteins and
the remarkable diversity of their functions, it should
come as no surprise that alterations in their structure
or expression might have serious pathophysiologic con-
sequences. Such alterations may either increase or de-
crease the activity of the affected G protein.
A dramatic example of decreased function was dis-
covered in patients with pseudohypoparathyroidism
(Albright’s hereditary osteodystrophy), which is a syn-
drome of generalized resistance to the action of a vari-
ety of hormones combined with several dysmorphic
characteristics. Most patients with this disorder have a
50 percent reduction in the activity of G
 
s
 
, the G protein
 
Figure 1. Mechanism of Activation and Action of G Proteins.
In the “off,” or resting, state, guanosine diphosphate (GDP) is tightly bound to the 
 
a 
 
subunit of the G protein. When the membrane
receptor is activated by the binding of a hormone (first messenger), it interacts with the G protein, causing GDP to dissociate from the
 
a
 
 subunit. GDP is replaced by guanosine triphosphate (GTP), which activates the G protein and leads to its dissociation into 
 
a
 
-subunit
and 
 
bg
 
-subunit complexes, either of which can activate effectors (the “on” state). The 
 
a
 
 subunit quickly hydrolyzes GTP to GDP, an
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action that inactivates the 
 
a
 
 subunit, allows it to reassociate with the 
 
bg
 
 complex, and resets the switch to the off position.
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that mediates the activation of adenylate cyclase in re-
sponse to hormones such as parathyroid hormone, thy-
rotropin, and gonadotropins. A number of distinct
germ-line mutations affecting the 
 
a
 
 subunit of the G
 
s
 
protein (G
 
s
 
a
 
), which disrupt either the protein or the
synthesis of its messenger RNA, are responsible for the
defect.
The activity of the G protein is increased in intestin-
al epithelial cells of patients with secretory diarrhea
caused by infection with 
 
Vibrio cholerae
 
. The bacteria se-
crete an exotoxin that catalyzes the adenosine diphos-
phate ribosylation (a specific chemical alteration) of a
specific arginine in G
 
s
 
a
 
. This drastically reduces the
GTPase activity, which normally functions to turn off
the G-protein switch, thereby causing continued activa-
tion of G
 
s
 
 and formation of cAMP and ultimately leads
to the increased fluid and electrolyte transport that
causes the diarrhea.
Somatic mutations that activate G proteins are also
known. Up to 40 percent of patients with acromegaly
due to pituitary somatotroph tumors have constitutively
activated adenylate cyclase in the tumor cells because
of mutations affecting G
 
s
 
a
 
 that reduce GTPase activity.
The resultant elevation of intracellular cAMP levels
leads to hypersecretion of growth hormone and cellular
proliferation. Some autonomously functioning thyroid
adenomas have similar mutations.
The McCune–Albright syndrome consists of hyper-
function of one or more endocrine glands (pituitary so-
matotrophs, adrenal cortex, thyroid, and gonads) cou-
pled with café au lait spots and polyostotic fibrous
dysplasia. It also appears to be caused by activating
mutations in the gene for G
 
s
 
a
 
, which probably occur
early in embryonic development. Affected persons ex-
press this mutation in a mosaic pattern that correlates
with the cellular abnormalities observed.
Finally, two patients have been described with the
seemingly paradoxical pairing of “testotoxicosis” (pre-
cocious puberty due to the hypersecretion of testoster-
one by Leydig cells) and pseudohypoparathyroidism
(hormone resistance). This is caused by a single muta-
tion in the gene for G
 
s
 
a
 
 that activates G
 
s
 
 
 
(by enhancing
the rate of release of GDP), leading to increased secre-
tion of cAMP and testosterone by the Leydig cells.
However, the altered protein is unstable at 37
 

 
C, ex-
plaining the pseudohypoparathyroid phenotype in all
tissues except the testes, which are generally 3
 

 
C to
5
 

 
C cooler than the rest of the body.
Similar syndromes involving abnormalities in G pro-
tein–coupled signal transduction pathways can also be
caused by alterations in either the upstream (receptor)
or downstream (effector) partners of the G proteins or
even by other proteins that regulate their function. Sev-
eral examples due to constitutively activated mutant re-
ceptors have already been described. Thus, the basic
discoveries of Gilman and Rodbell have already laid
the foundation for new insights into the pathogenesis of
various human diseases.
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